Cardiovascular physiology

Retia Medical’s Innovative Argos Cardiac Output Monitors Now Used at World-Renowned Academic Medical Center

Retrieved on: 
Monday, November 2, 2020
Medical specialties, Medicine, Intensive care medicine, Clinical medicine, Cardiac output, Cardiovascular physiology, Resuscitation, Monitoring

VALHALLA, N.Y., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Retia Medical is pleased to announce the successful installation of its Argos Cardiac Output monitors within the Duke University Health System.

Key Points: 
  • VALHALLA, N.Y., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Retia Medical is pleased to announce the successful installation of its Argos Cardiac Output monitors within the Duke University Health System.
  • This provides access to Retia Medicals industry-leading hemodynamic monitoring technology to help guide clinical decisions during volume resuscitation and vasoactive therapy for critically ill patients.
  • Marc Zemel, co-Founder and CEO of Retia Medical said, As a Duke alumnus, I appreciate Dukes reputation of being a pioneering institution.
  • Retia Medicals Argos Monitor, with its Multi-Beat Analysis (MBA) algorithm, eliminates a critical problem with older cardiac output technologies.

Worldwide Industry for Transportable Perfusion Systems to 2025 - Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 2, 2020
Medical devices, Health, Branches of biology, Physiology, Cardiovascular physiology, Perfusion, Respiratory physiology, Underwater diving physiology

Key points of Transportable Perfusion System Market Report:

Key Points: 
  • Key points of Transportable Perfusion System Market Report:
    The report provides a basic overview of Transportable Perfusion System industry including: definition, applications and manufacturing technology.
  • The report explores Global and Chinese major players in Transportable Perfusion System market.
  • The global Transportable Perfusion System market is further divided by company, by country, and by application/type for the competitive landscape analysis.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Transportable Perfusion System market covering all important parameters.

Pulse Biosciences Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020

Retrieved on: 
Wednesday, October 28, 2020
Biotechnology, Pharmaceutical, Health, Medical devices, Branches of biology, Magazines, Cardiovascular physiology, Pulse, Bioelectromagnetics, Articles

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020.
  • Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers.
  • Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve and extend the lives of patients.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

OMRON Healthcare Urges Regular Blood Pressure Monitoring for All U.S. Adults in Response to Surgeon General's Call to Action on Hypertension Control

Retrieved on: 
Tuesday, October 27, 2020
Physical quantities, Branches of biology, Physiology, Cardiovascular physiology, Pressure, Medical equipment, Hypertension, Blood pressure, Omron, Sphygmomanometer, Ambulatory blood pressure

LAKE FOREST, Ill., Oct. 27, 2020 /PRNewswire/ -- OMRON Healthcare, Inc. is urging regular blood pressure monitoring for all U.S. adults in response to U.S.

Key Points: 
  • LAKE FOREST, Ill., Oct. 27, 2020 /PRNewswire/ -- OMRON Healthcare, Inc. is urging regular blood pressure monitoring for all U.S. adults in response to U.S.
  • "For many patients there may be a need for regular blood pressure monitoring in addition to what is offered during physician visits.
  • Blood pressure fluctuates throughout the day, so true blood pressure is a representation of multiple measurements that show readings over time.
  • OMRON is sharing four steps that all Americans can take to address hypertension as a national health priority:
    Make monitoring your blood pressure a habit.

Texas Adopts Audacious Inquiry's PULSE Enterprise to Support Disaster Response

Retrieved on: 
Monday, October 19, 2020
Medical specialties, Health, Medicine, Health informatics, Cardiovascular physiology, Allergy, Immune system, RTT, Medical record, Pulse

PULSE is a cloud-based software solution that allows electronic patient data to be viewed by providers in nonroutine healthcare settings during disaster response.

Key Points: 
  • PULSE is a cloud-based software solution that allows electronic patient data to be viewed by providers in nonroutine healthcare settings during disaster response.
  • With PULSE, authenticated providers can access medications, allergies, diagnoses, and lab results for patients who are displaced outside of their normal healthcare environment.
  • Once PULSE is deployed in a state, it can quickly be activated since widespread disasters can occur at a moment's notice.
  • PULSE Enterprise will be an integral tool in Texas' hurricane readiness efforts.

Global Digital Blood Pressure Monitors Market- Featuring A&D Co. Ltd., Care Touch, ERKA. Kallmeyer Medizintechnik GmbH & Co. KG, General Electric Co., Among Others

Retrieved on: 
Thursday, October 15, 2020
Medical devices, Health, Branches of biology, Blood pressure, Cardiovascular physiology, Pressure, Physiology, Medical specialties, Monitoring, Sphygmomanometer, Ambulatory blood pressure, Computer monitor

The digital blood pressure monitors market is poised to grow by USD 1.54 billion during 2020-2024 progressing at a CAGR of about 10 % during the forecast period.

Key Points: 
  • The digital blood pressure monitors market is poised to grow by USD 1.54 billion during 2020-2024 progressing at a CAGR of about 10 % during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201015005585/en/
    Technavio has announced its latest market research report titled Global Digital Blood Pressure Monitors Market 2020-2024 (Graphic: Business Wire)
    The report on the digital blood pressure monitors market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • Download Free Sample Report on COVID-19 Recovery Analysis
    The digital blood pressure monitors market analysis includes the type segment and geographic landscapes.
  • This study identifies the growing demand for ambulatory blood pressure monitoring systems as one of the prime reasons driving the digital blood pressure monitors market growth during the next few years.

Cytokinetics Announces Data From Two Presentations at the HFSA Virtual Annual Scientific Meeting 2020

Retrieved on: 
Monday, October 5, 2020
Anatomy, Cytokinetics, Circulatory system, Branches of biology, Cardiovascular physiology, Heart diseases, Ejection fraction, Heart failure, Omecamtiv mecarbil

Real-World Population Representative of Patients Enrolled in GALACTIC-HFIndicate a High-Need, High-Risk Population with Heart Failure

Key Points: 
  • Real-World Population Representative of Patients Enrolled in GALACTIC-HFIndicate a High-Need, High-Risk Population with Heart Failure
    SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new data were presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020.
  • The clinical cohort included 3,955 patients matching the eMERGE network phenotype of HFrEF, with a left ventricular ejection fraction (LVEF) 40%.
  • The median age at index date for the clinical cohort was 65, and 61 for the GALACTIC-HF-like cohort.
  • Amgen holds an exclusive, worldwide license to omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization rights.

Daxor Corporation to Exhibit and Showcase Compelling New Data at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020 on the Value of BVA-100®

Retrieved on: 
Monday, September 28, 2020
Blood, Blood volume, Cardiovascular physiology

The Company will host a booth and will be available online throughout the entire conference to discuss how Daxors BVA-100 blood test improves heart failure outcomes and answer questions.

Key Points: 
  • The Company will host a booth and will be available online throughout the entire conference to discuss how Daxors BVA-100 blood test improves heart failure outcomes and answer questions.
  • Register for the event here: https://hfsa.org/annualscientificmeeting/registration
    Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement.
  • Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Dr. Jessica Isom Brings Real-World Clinical Experience and Expertise in Social Justice, Health Equity, and Mental Health to the Virgin Pulse Science Advisory Board

Retrieved on: 
Wednesday, September 23, 2020
Articles, Health, Cardiovascular physiology, Pulse, Virgin Group, Health equity, Mental health

We are thrilled to welcome Dr. Isom to the Virgin Pulse Science Advisory Board, said Rajiv Kumar, M.D., Virgin Pulses Chief Medical Officer and President of the Virgin Pulse Institute.

Key Points: 
  • We are thrilled to welcome Dr. Isom to the Virgin Pulse Science Advisory Board, said Rajiv Kumar, M.D., Virgin Pulses Chief Medical Officer and President of the Virgin Pulse Institute.
  • Though well documented, the connection between diversity, equity, inclusion, and physical, mental and social health is often underestimated by organizations and business leaders.
  • Dr. Isom is practicing physician with extensive experience in racial health disparities and ethnic mental health issues.
  • For more information about the Virgin Pulse Science Advisory Board and the Virgin Pulse Institute.

SANUWAVE Health Hosts Symposium on dermaPACE at Wounds Canada Virtual Conference

Retrieved on: 
Tuesday, September 22, 2020
Medical specialties, Branches of biology, Angiology, Physiology, Cardiovascular physiology, Revascularization, Vascular surgery, Angiogenesis, Perfusion

The biologic responses activated by the dermaPACE treatment continue to demonstrate improved revascularization and capillary perfusion needed to promote healing in these recalcitrant wounds.

Key Points: 
  • The biologic responses activated by the dermaPACE treatment continue to demonstrate improved revascularization and capillary perfusion needed to promote healing in these recalcitrant wounds.
  • The dermaPACE System has been particularly effective in speeding the healing process through improved microvascular perfusion in patients with diabetic, distal ischemia.
  • To participate in the conference and symposium free of charge, please send a request and your contact information [email protected].
  • The dermaPACE Systemand wound indications are currently licensed or approved in dozens of countries and regions around the world.